estramustine phosphate sodium
estramustine phosphate sodium is a pharmaceutical drug with 29 clinical trials. Historical success rate of 91.7%.
Success Metrics
Based on 22 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
15
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
88.0%
22 of 25 finished
12.0%
3 ended early
0
trials recruiting
29
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Clinical Trials (29)
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 29